Metabolism of a Serotonin-4 Receptor Partial Agonist 4-{4-[4-Tetrahydrofuran-3-yloxy)-Benzo[d]Isoxazol-3-yloxymethyl]-Piperidin-1-ylmethyl}-Tetrahydropyran-4-ol (TBPT): Identification of an Unusual Pharmacologically Active Cyclized Oxazolidine Metabolite in Human
4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial agonist of the human serotonin-4 (5-HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in...
Saved in:
Published in | Journal of pharmaceutical sciences Vol. 102; no. 9; pp. 3277 - 3293 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Elsevier Inc
01.09.2013
Wiley Subscription Services, Inc., A Wiley Company Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial agonist of the human serotonin-4 (5-HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in vitro in human liver microsomes and human hepatocytes. Metabolites were also identified in the plasma of healthy human subjects in a phase 1 clinical study. Human-derived metabolite profiles were compared with corresponding profiles obtained in laboratory animal species. There were two major routes of metabolism in vitro: N-dealkylation of the methyltetrahydropyran moiety (M1) and hydroxylation at the seven position of the benzisoxazole moiety (M4). These were also observed in human plasma; however, in that matrix, the major metabolite was an unusual cyclized oxazolidine entity (M2). M2 was proposed to be formed via generation of an intermediate 4° iminium ion on the piperidine ring followed by spontaneous cyclization by attack of the β-hydroxyl substituent of the tetrahydropyran ring to form a cyclized oxazolidine product. An authentic standard of the metabolite was generated using a methylene-blue-sensitized photochemical oxidation reaction as well as microbial transformation. Further investigation of this metabolite showed that it also possessed 5-HT4 agonism activity similar to the parent. The metabolite was 150-fold more highly protein bound in human plasma than TBPT, which is consistent with its presence as a major circulating metabolite while being only a minor metabolite in in vitro systems. Overall, this illustrates the importance of understanding the complex dispositional properties of a pharmacologically active metabolite. |
---|---|
AbstractList | 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial agonist of the human serotonin-4 (5-HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in vitro in human liver microsomes and human hepatocytes. Metabolites were also identified in the plasma of healthy human subjects in a phase 1 clinical study. Human-derived metabolite profiles were compared with corresponding profiles obtained in laboratory animal species. There were two major routes of metabolism in vitro: N-dealkylation of the methyltetrahydropyran moiety (M1) and hydroxylation at the seven position of the benzisoxazole moiety (M4). These were also observed in human plasma; however, in that matrix, the major metabolite was an unusual cyclized oxazolidine entity (M2). M2 was proposed to be formed via generation of an intermediate 4° iminium ion on the piperidine ring followed by spontaneous cyclization by attack of the β-hydroxyl substituent of the tetrahydropyran ring to form a cyclized oxazolidine product. An authentic standard of the metabolite was generated using a methylene-blue-sensitized photochemical oxidation reaction as well as microbial transformation. Further investigation of this metabolite showed that it also possessed 5-HT4 agonism activity similar to the parent. The metabolite was 150-fold more highly protein bound in human plasma than TBPT, which is consistent with its presence as a major circulating metabolite while being only a minor metabolite in in vitro systems. Overall, this illustrates the importance of understanding the complex dispositional properties of a pharmacologically active metabolite. 4‐{4‐[4‐Tetrahydrofuran‐3‐yloxy)‐benzo[d]isoxazol‐3‐yloxymethyl]‐piperidin‐1‐ylmethyl}‐tetrahydropyran‐4‐ol (PF‐4995274, TBPT) is a new agent that is a partial agonist of the human serotonin‐4 (5‐HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in vitro in human liver microsomes and human hepatocytes. Metabolites were also identified in the plasma of healthy human subjects in a phase 1 clinical study. Human‐derived metabolite profiles were compared with corresponding profiles obtained in laboratory animal species. There were two major routes of metabolism in vitro: N‐dealkylation of the methyltetrahydropyran moiety (M1) and hydroxylation at the seven position of the benzisoxazole moiety (M4). These were also observed in human plasma; however, in that matrix, the major metabolite was an unusual cyclized oxazolidine entity (M2). M2 was proposed to be formed via generation of an intermediate 4° iminium ion on the piperidine ring followed by spontaneous cyclization by attack of the β‐hydroxyl substituent of the tetrahydropyran ring to form a cyclized oxazolidine product. An authentic standard of the metabolite was generated using a methylene‐blue‐sensitized photochemical oxidation reaction as well as microbial transformation. Further investigation of this metabolite showed that it also possessed 5‐HT4 agonism activity similar to the parent. The metabolite was 150‐fold more highly protein bound in human plasma than TBPT, which is consistent with its presence as a major circulating metabolite while being only a minor metabolite in in vitro systems. Overall, this illustrates the importance of understanding the complex dispositional properties of a pharmacologically active metabolite. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3277–3293, 2013 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-p iper idin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial agonist of the human serotonin-4 (5-HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in vitro in human liver microsomes and human hepatocytes. Metabolites were also identified in the plasma of healthy human subjects in a phase 1 clinical study. Human-derived metabolite profiles were compared with corresponding profiles obtained in laboratory animal species. There were two major routes of metabolism in vitro: N-dealkylation of the methyltetrahydropyran moiety (M1) and hydroxylation at the seven position of the benzisoxazole moiety (M4). These were also observed in human plasma; however, in that matrix, the major metabolite was an unusual cyclized oxazolidine entity (M2). M2 was proposed to be formed via generation of an intermediate 4 degree iminium ion on the piperidine ring followed by spontaneous cyclization by attack of the [beta]-hydroxyl substituent of the tetrahydropyran ring to form a cyclized oxazolidine product. An authentic standard of the metabolite was generated using a methylene-blue-sensitized photochemical oxidation reaction as well as microbial transformation. Further investigation of this metabolite showed that it also possessed 5-HT4 agonism activity similar to the parent. The metabolite was 150-fold more highly protein bound in human plasma than TBPT, which is consistent with its presence as a major circulating metabolite while being only a minor metabolite in in vitro systems. Overall, this illustrates the importance of understanding the complex dispositional properties of a pharmacologically active metabolite. [copy 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3277-3293, 2013 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial agonist of the human serotonin-4 (5-HT4) receptor and is under investigation for neurological disorders. Metabolism of TBPT was examined in vitro in human liver microsomes and human hepatocytes. Metabolites were also identified in the plasma of healthy human subjects in a phase 1 clinical study. Human-derived metabolite profiles were compared with corresponding profiles obtained in laboratory animal species. There were two major routes of metabolism in vitro: N-dealkylation of the methyltetrahydropyran moiety (M1) and hydroxylation at the seven position of the benzisoxazole moiety (M4). These were also observed in human plasma; however, in that matrix, the major metabolite was an unusual cyclized oxazolidine entity (M2). M2 was proposed to be formed via generation of an intermediate 4° iminium ion on the piperidine ring followed by spontaneous cyclization by attack of the [beta]-hydroxyl substituent of the tetrahydropyran ring to form a cyclized oxazolidine product. An authentic standard of the metabolite was generated using a methylene-blue-sensitized photochemical oxidation reaction as well as microbial transformation. Further investigation of this metabolite showed that it also possessed 5-HT4 agonism activity similar to the parent. The metabolite was 150-fold more highly protein bound in human plasma than TBPT, which is consistent with its presence as a major circulating metabolite while being only a minor metabolite in in vitro systems. Overall, this illustrates the importance of understanding the complex dispositional properties of a pharmacologically active metabolite. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3277-3293, 2013 [PUBLICATION ABSTRACT] |
Author | Rapp, Tracey Brodney, Michael A. Lee, Carlos Obach, R. Scott Coffman, Karen J. Ryder, Tim F. Walker, Gregory S. Vanase-Frawley, Michelle A. Wong, John W. Miller, Emily Sawant-Basak, Aarti Tseng, Elaine |
Author_xml | – sequence: 1 givenname: Aarti surname: Sawant-Basak fullname: Sawant-Basak, Aarti – sequence: 2 givenname: Karen J. surname: Coffman fullname: Coffman, Karen J. – sequence: 3 givenname: Gregory S. surname: Walker fullname: Walker, Gregory S. – sequence: 4 givenname: Tim F. surname: Ryder fullname: Ryder, Tim F. – sequence: 5 givenname: Elaine surname: Tseng fullname: Tseng, Elaine – sequence: 6 givenname: Emily surname: Miller fullname: Miller, Emily – sequence: 7 givenname: Carlos surname: Lee fullname: Lee, Carlos – sequence: 8 givenname: Michelle A. surname: Vanase-Frawley fullname: Vanase-Frawley, Michelle A. – sequence: 9 givenname: John W. surname: Wong fullname: Wong, John W. – sequence: 10 givenname: Michael A. surname: Brodney fullname: Brodney, Michael A. – sequence: 11 givenname: Tracey surname: Rapp fullname: Rapp, Tracey – sequence: 12 givenname: R. Scott surname: Obach fullname: Obach, R. Scott email: r.scott.obach@pfizer.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23589342$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkl1PFDEUhkeD4Usv_AOmiTdwUejXzM54B0RlDYaNLFeETLqdM1DSade2gwzG_253lzXGaLxpk_M-fc9Hz062YZ2FLHtNyQElhB3ezcMB47lgz7NtmjOCC0JHG9l20hhO8Wor2wnhjhBSkDzfzLYSXFZcsO1nm58hypkzOnTItUiiC_AuOqstFugLKJhH59FE-qilQUc3SQkRCfxd4CuBpxC9vB0a79reS4s5Hox7GPbxMdhHd9Vcj4N7kI_OrJUO4u1grvFEz8HrJmWhSVhFf_xmNx8WdgI7g_amx5Pp_js0bsBG3Wolo3Z2WaxFl7YPfSpscit9J5Uz7iYBxgzoSEV9D-hkUEY_QoPOl3UsUgJa9xwBaYtO-07al9mLVpoAr57u3ezyw_vpySk-O_84Pjk6w0oUOcNVkVdFOigoxksuQJCiUg2vmjRlKakqS97OgLXNjDPCc9nOFB21ssz5iLKS8d1sb-U79-5rDyHWnQ4KjJEWXB9qWvIRp0Uliv-jgqX_HNE8T-jbP9A713ubGkkUXZiJEUnU_opS3oXgoa3nXnfSDzUl9WKR6rRI9XKREvvmybGfddD8Itebk4DDFfBNGxj-7VR_mlysLfnqBaT53mvwdVAarIJGe1Cxbpz-SyE_AcNO6FE |
CODEN | JPMSAE |
CitedBy_id | crossref_primary_10_1124_dmd_116_071084 crossref_primary_10_1016_j_bcp_2020_113796 crossref_primary_10_1039_D0MD00370K crossref_primary_10_3109_00498254_2016_1152522 crossref_primary_10_1021_acs_jmedchem_8b00457 crossref_primary_10_1021_acs_chemrestox_6b00332 crossref_primary_10_1007_s40265_014_0217_5 crossref_primary_10_1124_dmd_117_078279 crossref_primary_10_1517_13543776_2015_1027192 crossref_primary_10_1021_acs_jmedchem_3c01293 crossref_primary_10_1124_pr_118_015552 crossref_primary_10_1111_cts_12734 crossref_primary_10_1016_j_pneurobio_2016_04_001 |
Cites_doi | 10.1016/S0165-6147(00)89081-1 10.1074/jbc.M109008200 10.2165/11539530-000000000-00000 10.1007/s11095-006-9780-0 10.1016/S0531-5565(02)00157-2 10.1097/00001756-199406020-00018 10.3233/JAD-2008-15404 10.1016/j.neuropharm.2007.06.016 10.1038/clpt.1981.56 10.1007/s002130050529 10.1021/jm300953p 10.1016/0040-4020(75)80145-1 10.1124/dmd.110.034637 10.1021/tx8004357 10.1002/bdd.325 10.1016/S0028-3908(96)00169-4 10.2174/1567205043332252 |
ContentType | Journal Article |
Copyright | 2013 Wiley Periodicals, Inc. and the American Pharmacists Association Copyright © 2013 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2013 Wiley Periodicals, Inc. and the American Pharmacists Association – notice: Copyright © 2013 Wiley Periodicals, Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7QP 7QR 7TK 7U7 8FD C1K FR3 P64 RC3 7X8 |
DOI | 10.1002/jps.23542 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Toxicology Abstracts MEDLINE Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-6017 |
EndPage | 3293 |
ExternalDocumentID | 3042436741 10_1002_jps_23542 23589342 JPS23542 S0022354915309254 |
Genre | article Journal Article |
GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 1ZS 31~ 33P 36B 3O- 3WU 4.4 457 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAEVG AAHHS AAIAV AAKUH AALRI AAOIN AAONW AAXUO AAYOK AAZKR ABCQN ABEML ABFRF ABIJN ABJNI ABMAC ABOCM ABPVW ABWRO ACBWZ ACCFJ ACGFO ACGFS ACIWK ACPRK ACSCC ACXME ACXQS ADBBV ADIZJ AEEZP AEFWE AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFRAH AFTJW AFZJQ AGHFR AI. AITUG AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ ATUGU AZBYB BAFTC BDRZF BFHJK BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DU5 E3Z EBD EBS EJD EMB EMOBN ESTFP F00 F01 F04 F5P FDB FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HHY HHZ HOLLA HVGLF HX~ HZ~ IX1 J0M JPC KQQ L7B LAW LC2 LC3 LH4 LP6 LP7 LSO LW6 M41 M6Q MK0 MK4 N04 N05 N9A NF~ NNB O66 O9- P2P P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RX1 RYL SSZ SUPJJ SV3 UB1 UKR UNMZH V2E V8K VH1 W8V W99 WBFHL WH7 WIB WJL WQJ WRC WUP WWP WYUIH XG1 XPP XV2 Y6R YCJ ZE2 ZGI ZXP ~IA ~WT ADVLN AKRWK OIG 1OB AFJKZ CGR CUY CVF ECM EIF NPM AAYXX ACRPL CITATION 7QO 7QP 7QR 7TK 7U7 8FD C1K FR3 P64 RC3 7X8 |
ID | FETCH-LOGICAL-c4652-965969651ec23834e4069cd39d549aa1c883fbe2fdb32035afbc17fa853712823 |
IEDL.DBID | DR2 |
ISSN | 0022-3549 |
IngestDate | Fri Oct 25 04:03:21 EDT 2024 Fri Oct 25 11:55:12 EDT 2024 Thu Oct 10 22:06:57 EDT 2024 Fri Dec 06 01:58:51 EST 2024 Sat Sep 28 08:02:39 EDT 2024 Sat Aug 24 01:02:01 EDT 2024 Fri Feb 23 02:30:59 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | mass spectrometry metabolism protein binding microsomes hepatic metabolism |
Language | English |
License | Copyright © 2013 Wiley Periodicals, Inc. https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4652-965969651ec23834e4069cd39d549aa1c883fbe2fdb32035afbc17fa853712823 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://jpharmsci.org/article/S0022354915309254/pdf |
PMID | 23589342 |
PQID | 1419463470 |
PQPubID | 1006386 |
PageCount | 17 |
ParticipantIDs | proquest_miscellaneous_1837316946 proquest_miscellaneous_1420607155 proquest_journals_1419463470 crossref_primary_10_1002_jps_23542 pubmed_primary_23589342 wiley_primary_10_1002_jps_23542_JPS23542 elsevier_sciencedirect_doi_10_1002_jps_23542 |
PublicationCentury | 2000 |
PublicationDate | September 2013 |
PublicationDateYYYYMMDD | 2013-09-01 |
PublicationDate_xml | – month: 09 year: 2013 text: September 2013 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: United States – name: Washington |
PublicationTitle | Journal of pharmaceutical sciences |
PublicationTitleAlternate | J Pharm Sci |
PublicationYear | 2013 |
Publisher | Elsevier Inc Wiley Subscription Services, Inc., A Wiley Company Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Wiley Subscription Services, Inc., A Wiley Company – name: Elsevier Limited |
References | Gao, Deng, Obach (bb0075) 2010; 38 Kalvass, Maurer (bb0090) 2002; 23 Hubert-Brierre, Herlem, Khuong-Huu (bb0070) 1975; 31 Syvaenen, Xie, Sahin, Hammarlund-Udenaes (bb0085) 2006; 23 Cappell, Herrmann, Cornish, Lanctot (bb0015) 2010; 24 Consolo, Arnaboldi, Giorgi, Russi, Ladinsky (bb0025) 1994; 5 Brodney, Johnson, Sawant-Basak, Coffman, Drummond, Hudson, Fisher, Noguchi, Waizumi, McDowell (bb0065) 2012; 55 Mohler, Shacham, Noiman, Lezoualc'h, Robert, Gastineau, Rutkowski, Marantz, Dumuis, Bockaert, Gold, Ragozzino (bb0050) 2007; 53 Letty, Child, Dumuis, Pantaloni, Bockaert, Rondouin (bb0040) 1997; 36 Wilcock, Colton (bb0010) 2008; 15 Hamilton, Garnett, Kline (bb0080) 1981; 29 Dalvie, Obach, Kang, Prakash, Loi, Hurst, Nedderman, Goulet, Smith, Bu, Smith (bb0095) 2009; 22 Maillet, Robert, Lezoualc'h (bb0045) 2004; 1 Lezoualc'h, Robert (bb0060) 2003; 38 Eglen RM, Wong EHF, Dumuis A, Bockaert J. Central 5-HT4 receptors 1995. Trends Pharmacol Sci 16:391–397. Robert, Zugaza, Fischmeister, Gardier, Lezoualc'h (bb0055) 2001; 276 Terry, Buccafusco, Jackson, Prendergast, Fontana, Wong, Bonhaus, Weller, Eglen (bb0035) 1998; 135 Mohler, Shacham, Noiman, Lezoualc'h, Robert, Gastineau, Rutkowski, Marantz, Dumuis, Bockaert, Gold, Ragozzino (bb0030) 2007; 53 2001; 276 2009; 22 2010; 38 16 2010; 24 2006; 23 2002; 23 1997; 36 2008; 15 2003; 38 1975; 31 1981; 29 2004; 1 2007; 53 1998; 135 2012; 55 1994; 5 Terry (10.1002/jps.23542_bb0035) 1998; 135 10.1002/jps.23542_bb0020 Hamilton (10.1002/jps.23542_bb0080) 1981; 29 Consolo (10.1002/jps.23542_bb0025) 1994; 5 Hubert-Brierre (10.1002/jps.23542_bb0070) 1975; 31 Wilcock (10.1002/jps.23542_bb0010) 2008; 15 Letty (10.1002/jps.23542_bb0040) 1997; 36 Maillet (10.1002/jps.23542_bb0045) 2004; 1 Dalvie (10.1002/jps.23542_bb0095) 2009; 22 Robert (10.1002/jps.23542_bb0055) 2001; 276 Lezoualc'h (10.1002/jps.23542_bb0060) 2003; 38 Brodney (10.1002/jps.23542_bb0065) 2012; 55 Syvaenen (10.1002/jps.23542_bb0085) 2006; 23 Cappell (10.1002/jps.23542_bb0015) 2010; 24 Mohler (10.1002/jps.23542_bb0050) 2007; 53 Kalvass (10.1002/jps.23542_bb0090) 2002; 23 Gao (10.1002/jps.23542_bb0075) 2010; 38 Mohler (10.1002/jps.23542_bb0030) 2007; 53 |
References_xml | – volume: 38 start-page: 159 year: 2003 end-page: 166 ident: bb0060 article-title: The serotonin 5-HT4 receptor and the amyloid precursor protein processing publication-title: Exp Gerontol contributor: fullname: Robert – volume: 38 start-page: 2147 year: 2010 end-page: 2156 ident: bb0075 article-title: A simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments publication-title: Drug Metab Dispos contributor: fullname: Obach – volume: 55 start-page: 9240 year: 2012 end-page: 9254 ident: bb0065 article-title: Identification of multiple 5-HT4 partial agonist clinical candidates for the treatment of Alzheimer's disease publication-title: J Med Chem contributor: fullname: McDowell – volume: 1 start-page: 79 year: 2004 end-page: 85 ident: bb0045 article-title: New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer's disease publication-title: Curr Alzheim Res contributor: fullname: Lezoualc'h – volume: 15 start-page: 555 year: 2008 end-page: 569 ident: bb0010 article-title: Anti-amyloid-β immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials publication-title: J Alzheimers Dis contributor: fullname: Colton – volume: 53 start-page: 563 year: 2007 end-page: 573 ident: bb0030 article-title: VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux publication-title: Neuropharmacol contributor: fullname: Ragozzino – volume: 31 start-page: 3049 year: 1975 end-page: 3054 ident: bb0070 article-title: Photochemical oxidation of tertiary amines and alkaloids. VI. Photosensitized oxidation of alkaloids containing an N-methyl heterocycle (nicotine, N-methyl anabasine, ajmaline) publication-title: Tetrahedron contributor: fullname: Khuong-Huu – volume: 22 start-page: 357 year: 2009 end-page: 368 ident: bb0095 article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites publication-title: Chem Res Toxicol contributor: fullname: Smith – volume: 5 start-page: 1230 year: 1994 end-page: 1232 ident: bb0025 article-title: 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex publication-title: Neuroreport contributor: fullname: Ladinsky – volume: 29 start-page: 409 year: 1981 end-page: 413 ident: bb0080 article-title: Mean serum level determination by assay of a single pooled sample publication-title: Clin Pharmacol Ther contributor: fullname: Kline – volume: 23 start-page: 705 year: 2006 end-page: 717 ident: bb0085 article-title: Pharmacokinetic consequences of active drug efflux at the blood–brain barrier publication-title: Pharm Res contributor: fullname: Hammarlund-Udenaes – volume: 135 start-page: 407 year: 1998 end-page: 415 ident: bb0035 article-title: Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017 publication-title: Psychopharmacol contributor: fullname: Eglen – volume: 276 start-page: 44881 year: 2001 end-page: 44888 ident: bb0055 article-title: The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. 2001 publication-title: J Biol Chem contributor: fullname: Lezoualc'h – volume: 24 start-page: 909 year: 2010 end-page: 927 ident: bb0015 article-title: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease publication-title: CNS Drugs contributor: fullname: Lanctot – volume: 36 start-page: 681 year: 1997 end-page: 687 ident: bb0040 article-title: 5-HT4 receptors improve social olfactory memory in the rat publication-title: Neuropharmacol contributor: fullname: Rondouin – volume: 53 start-page: 563 year: 2007 end-page: 573 ident: bb0050 article-title: VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux publication-title: Neuropharmacol contributor: fullname: Ragozzino – volume: 23 start-page: 327 year: 2002 end-page: 338 ident: bb0090 article-title: Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery publication-title: Biopharm Drug Dispos contributor: fullname: Maurer – volume: 15 start-page: 555 year: 2008 end-page: 569 article-title: Anti‐amyloid‐β immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials publication-title: J Alzheimers Dis – volume: 38 start-page: 159 year: 2003 end-page: 166 article-title: The serotonin 5‐HT4 receptor and the amyloid precursor protein processing publication-title: Exp Gerontol – volume: 31 start-page: 3049 year: 1975 end-page: 3054 article-title: Photochemical oxidation of tertiary amines and alkaloids. VI. Photosensitized oxidation of alkaloids containing an N‐methyl heterocycle (nicotine, N‐methyl anabasine, ajmaline) publication-title: Tetrahedron – volume: 38 start-page: 2147 year: 2010 end-page: 2156 article-title: A simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments publication-title: Drug Metab Dispos – volume: 23 start-page: 327 year: 2002 end-page: 338 article-title: Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery publication-title: Biopharm Drug Dispos – volume: 23 start-page: 705 year: 2006 end-page: 717 article-title: Pharmacokinetic consequences of active drug efflux at the blood–brain barrier publication-title: Pharm Res – volume: 53 start-page: 563 year: 2007 end-page: 573 article-title: VRX‐03011, a novel 5‐HT4 agonist, enhances memory and hippocampal acetylcholine efflux publication-title: Neuropharmacol – volume: 36 start-page: 681 year: 1997 end-page: 687 article-title: 5‐HT4 receptors improve social olfactory memory in the rat publication-title: Neuropharmacol – volume: 29 start-page: 409 year: 1981 end-page: 413 article-title: Mean serum level determination by assay of a single pooled sample publication-title: Clin Pharmacol Ther – volume: 22 start-page: 357 year: 2009 end-page: 368 article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites publication-title: Chem Res Toxicol – volume: 16 start-page: 391 end-page: 397 article-title: Central 5‐HT4 receptors 1995 publication-title: Trends Pharmacol Sci – volume: 5 start-page: 1230 year: 1994 end-page: 1232 article-title: 5‐HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex publication-title: Neuroreport – volume: 24 start-page: 909 year: 2010 end-page: 927 article-title: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease publication-title: CNS Drugs – volume: 276 start-page: 44881 year: 2001 end-page: 44888 article-title: The human serotonin 5‐HT4 receptor regulates secretion of non‐amyloidogenic precursor protein. 2001 publication-title: J Biol Chem – volume: 135 start-page: 407 year: 1998 end-page: 415 article-title: Enhanced delayed matching performance in younger and older macaques administered the 5‐HT4 receptor agonist, RS 17017 publication-title: Psychopharmacol – volume: 1 start-page: 79 year: 2004 end-page: 85 article-title: New insights into serotonin 5‐HT4 receptors: A novel therapeutic target for Alzheimer's disease publication-title: Curr Alzheim Res – volume: 55 start-page: 9240 year: 2012 end-page: 9254 article-title: Identification of multiple 5‐HT4 partial agonist clinical candidates for the treatment of Alzheimer's disease publication-title: J Med Chem – ident: 10.1002/jps.23542_bb0020 doi: 10.1016/S0165-6147(00)89081-1 – volume: 276 start-page: 44881 year: 2001 ident: 10.1002/jps.23542_bb0055 article-title: The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. 2001 publication-title: J Biol Chem doi: 10.1074/jbc.M109008200 contributor: fullname: Robert – volume: 24 start-page: 909 year: 2010 ident: 10.1002/jps.23542_bb0015 article-title: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease publication-title: CNS Drugs doi: 10.2165/11539530-000000000-00000 contributor: fullname: Cappell – volume: 23 start-page: 705 year: 2006 ident: 10.1002/jps.23542_bb0085 article-title: Pharmacokinetic consequences of active drug efflux at the blood–brain barrier publication-title: Pharm Res doi: 10.1007/s11095-006-9780-0 contributor: fullname: Syvaenen – volume: 38 start-page: 159 year: 2003 ident: 10.1002/jps.23542_bb0060 article-title: The serotonin 5-HT4 receptor and the amyloid precursor protein processing publication-title: Exp Gerontol doi: 10.1016/S0531-5565(02)00157-2 contributor: fullname: Lezoualc'h – volume: 5 start-page: 1230 year: 1994 ident: 10.1002/jps.23542_bb0025 article-title: 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex publication-title: Neuroreport doi: 10.1097/00001756-199406020-00018 contributor: fullname: Consolo – volume: 15 start-page: 555 year: 2008 ident: 10.1002/jps.23542_bb0010 article-title: Anti-amyloid-β immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials publication-title: J Alzheimers Dis doi: 10.3233/JAD-2008-15404 contributor: fullname: Wilcock – volume: 53 start-page: 563 year: 2007 ident: 10.1002/jps.23542_bb0030 article-title: VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux publication-title: Neuropharmacol doi: 10.1016/j.neuropharm.2007.06.016 contributor: fullname: Mohler – volume: 29 start-page: 409 year: 1981 ident: 10.1002/jps.23542_bb0080 article-title: Mean serum level determination by assay of a single pooled sample publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1981.56 contributor: fullname: Hamilton – volume: 53 start-page: 563 year: 2007 ident: 10.1002/jps.23542_bb0050 article-title: VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux publication-title: Neuropharmacol doi: 10.1016/j.neuropharm.2007.06.016 contributor: fullname: Mohler – volume: 135 start-page: 407 year: 1998 ident: 10.1002/jps.23542_bb0035 article-title: Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017 publication-title: Psychopharmacol doi: 10.1007/s002130050529 contributor: fullname: Terry – volume: 55 start-page: 9240 year: 2012 ident: 10.1002/jps.23542_bb0065 article-title: Identification of multiple 5-HT4 partial agonist clinical candidates for the treatment of Alzheimer's disease publication-title: J Med Chem doi: 10.1021/jm300953p contributor: fullname: Brodney – volume: 31 start-page: 3049 year: 1975 ident: 10.1002/jps.23542_bb0070 article-title: Photochemical oxidation of tertiary amines and alkaloids. VI. Photosensitized oxidation of alkaloids containing an N-methyl heterocycle (nicotine, N-methyl anabasine, ajmaline) publication-title: Tetrahedron doi: 10.1016/0040-4020(75)80145-1 contributor: fullname: Hubert-Brierre – volume: 38 start-page: 2147 year: 2010 ident: 10.1002/jps.23542_bb0075 article-title: A simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments publication-title: Drug Metab Dispos doi: 10.1124/dmd.110.034637 contributor: fullname: Gao – volume: 22 start-page: 357 year: 2009 ident: 10.1002/jps.23542_bb0095 article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites publication-title: Chem Res Toxicol doi: 10.1021/tx8004357 contributor: fullname: Dalvie – volume: 23 start-page: 327 year: 2002 ident: 10.1002/jps.23542_bb0090 article-title: Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.325 contributor: fullname: Kalvass – volume: 36 start-page: 681 year: 1997 ident: 10.1002/jps.23542_bb0040 article-title: 5-HT4 receptors improve social olfactory memory in the rat publication-title: Neuropharmacol doi: 10.1016/S0028-3908(96)00169-4 contributor: fullname: Letty – volume: 1 start-page: 79 year: 2004 ident: 10.1002/jps.23542_bb0045 article-title: New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer's disease publication-title: Curr Alzheim Res doi: 10.2174/1567205043332252 contributor: fullname: Maillet |
SSID | ssj0006055 |
Score | 2.2009058 |
Snippet | 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial... 4‐{4‐[4‐Tetrahydrofuran‐3‐yloxy)‐benzo[d]isoxazol‐3‐yloxymethyl]‐piperidin‐1‐ylmethyl}‐tetrahydropyran‐4‐ol (PF‐4995274, TBPT) is a new agent that is a partial... 4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-p iper idin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a... |
SourceID | proquest crossref pubmed wiley elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3277 |
SubjectTerms | Animals Blood Proteins - metabolism Brain - metabolism Cyclization Dealkylation Dogs Female Furans - chemistry Furans - metabolism Furans - pharmacokinetics Furans - pharmacology hepatic metabolism Hepatocytes - metabolism Humans Hydroxylation Male mass spectrometry metabolism microsomes Microsomes, Liver - metabolism Oxazoles - chemistry Oxazoles - metabolism Oxazoles - pharmacokinetics Oxazoles - pharmacology protein binding Rats Rats, Sprague-Dawley Receptors, Serotonin, 5-HT4 - metabolism Serotonin 5-HT4 Receptor Agonists - chemistry Serotonin 5-HT4 Receptor Agonists - metabolism Serotonin 5-HT4 Receptor Agonists - pharmacokinetics Serotonin 5-HT4 Receptor Agonists - pharmacology |
Title | Metabolism of a Serotonin-4 Receptor Partial Agonist 4-{4-[4-Tetrahydrofuran-3-yloxy)-Benzo[d]Isoxazol-3-yloxymethyl]-Piperidin-1-ylmethyl}-Tetrahydropyran-4-ol (TBPT): Identification of an Unusual Pharmacologically Active Cyclized Oxazolidine Metabolite in Human |
URI | https://dx.doi.org/10.1002/jps.23542 https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjps.23542 https://www.ncbi.nlm.nih.gov/pubmed/23589342 https://www.proquest.com/docview/1419463470 https://search.proquest.com/docview/1420607155 https://search.proquest.com/docview/1837316946 |
Volume | 102 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDbTnnjhfukYyCCYNqntmthJGnjiNk2ThiropEljimzHQd2yJCKJRIqQ-An8Rn4J59hJy4AhxEOtNHZ67OrzuTg-nwl5nMSMKc0hyJEwmzhT_kC6TAxin4d-GGrtMkwU3n_j7x7wvUPvcIU863JhLD_EYsENZ4bR1zjBhSy3l6ShJ0U5dJnHUf86LMDtfK_eLqmjwE33FkzhEAR1rEIjd3vx5EW26Hdf87zramzPzlXyvuu13XJyOqwrOVTzXwgd_3NY18iV1ielzy2IrpMVnd0gGxNLat306XSZo1X26QadLOmum5uXnuzrCpCUzsozmidUUAB1XuEq7_ev3zgFjaoLCOxpgSAFMeJDjmy9lEP1ZyyOsKh0BWqvicEs1GA-4Q6DT5PCiLfgQupsnh_Fx7My_yTmefpzPR6C3aTH8LWYIW9zbCQ7ptrWfTknoGisABSbp3Rz-mIy3XpKbcpy0q5hmqFktM7qsoZOF8shI6rThgpjKKhqVDqb65jafqFwTc_af6TSdJZRcwziLXKw83r6cnfQHj4xUNz33AESLfpQOFqBV8O4xhRhFbMwBjAJ4ajxmCVSu0ksmTtinkikcoJEgPsTgM132W2ymuWZvkuoFwQjKUPuxGzMtROOlQ9hpINZy44OQ9kjjzoYRoXlGIksm7QbARwiA4ce6XcAjVrnyDo9EWDoT83XOxBHrVYqIcxzQu4zHox65OGiGvQJviQSmc5rbOOOkHPQ8_7SZszwwDP4rR65YyfIouOYeh0y7MCmgfnFI4r2Ju_Mxdq_N71HLrvmPBLc5LdOVquPtb4PXmElH5jp_wN-WnN9 |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDbTeIAX7pfCAINg2qS2a2wnbRAv3KYy1qmCTpo0VVHiOFNHlkQkkUgREj-B38gv4Rw7aRkwhHiolcZOj119PhfH5zMhj6OQc6kEBDkBzCbBpdMJGPc7oSNcx3WVYhwThUd7znBf7BzYByvkWZMLY_ghFgtuODO0vsYJjgvSW0vW0OMs7zJuC1DA52G6W7ih69W7JXkUOOr2giscwqCGV6jHthaPnmWNfvc2Tzuv2vpsXybTpt9m08mHblkEXTn_hdLxfwd2hVyq3VL63ODoKllRyTWyPja81lWbTpZpWnmbrtPxkvG6un7uyUgVAKZ4lp_QNKI-BVynBS70fv_6TVBQqiqD2J5miFMQ4x-lSNhLBVR_xuIQi0IVoPmqECxDCRYU7nD4VDEMeRMuApXM08NwOsvTT_48jX-ux3Owq3gKX7MZUjeHWrKlq03dl1MCssoIQLFpTDcmL8aTzafUZC1H9TKmHkpCy6TMS-h0thwyAjuuqK9tBZWVjGdzFVLTLxSu6En9jxSKzhKqT0K8Qfa3X09eDjv1-RMdKRybdZBr0YHCUhIcGy4UZgnLkLshoMn3LTkY8ChQLAoDznrc9qNAWv3IBw-oD2af8ZtkNUkTdZtQu9_vBYErrJAPhLLcgXQgkrQwcdlSrhu0yKMGh15maEY8QyjNPICDp-HQIu0GoV7tHxm_xwMQ_an5WoNir1ZMOUR6liscLvq9Fnm4qAaVgu-J_ESlJbZhPaQdtO2_tBlwPPMMfqtFbpkZsug4Zl-7HDuwoXF-9oi8nfF7fXHn35s-IBeGk9Gut_tm7-1dcpHp40lwz98aWS0-luoeOIlFcF_rgh9CGHee |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDbTkBAv3C-FAQbBtElN19hO2sATMKox2FSxTpo0pihOHFTIkogkEilC4ifwG_klnGMnLQOGEA-10trp8ak-n4ub85mQh3HEeagEJDkSVpPgoWtJxgMrcoXnep5SjGOh8M6uu7Uvtg-cgyXypK2FMfwQ8w03XBnaXuMCz6N4Y0Ea-j4veow7AuzvWeEyD4nzN98suKMgTnfmVOGQBbW0Qn22Mb_1NGf0e7B5MnbVzmd0kbxtp22eOfnQq0rZC2e_MDr-p16XyIUmKKVPDYoukyWVXiGrY8NqXXfpZFGkVXTpKh0v-K7rq2ce7agSoJRMi2OaxTSggOqsxG3e71-_CQomVeWQ2dMcUQpigncZ0vVSAd2fsTnEplQl2L06Ar9Qgf-ETzi86gQ0XocLqdJZdhgdTYvsUzDLkp_78RTsOjmCt_kUiZsjLdnW3abvywkBeW0EoNgsoWuTZ-PJ-mNqapbjZhNTq5LSKq2KCiadL1RGWCc1DbSnoGEdJtOZiqiZFwpX9Lj5RUpFpynV5yBeI_ujF5PnW1Zz-oQVCtdhFjItutDYKoSwhguFNcJhxL0IwBQEdjgc8lgqFkeSsz53gliG9iAOIP4ZgNNn_DpZTrNU3STUGQz6UnrCjvhQKNsbhi7kkTaWLdvK82SHPGhh6OeGZMQ3dNLMBzj4Gg4d0m0B6jfRkYl6fMDQn4avtCD2G7NUQJ5ne8LlYtDvkPvzbjAo-C9RkKqswjGsj6SDjvOXMUOOJ57Bd3XIDbNA5hPH2muP4wTWNMxP18jfHu_pi1v_PvQeOTfeHPmvX-6-uk3OM302CT7wt0KWy4-VugMRYinvakvwA7mZdk0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolism+of+a+serotonin-4+receptor+partial+agonist+4-%7B4-%5B4-tetrahydrofuran-3-yloxy%29-benzo%5Bd%5Disoxazol-3-yloxymethyl%5D-piperidin-1-ylmethyl%7D-tetrahydropyran-4-ol+%28TBPT%29%3A+identification+of+an+unusual+pharmacologically+active+cyclized+oxazolidine+metabolite+in+human&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Sawant-Basak%2C+Aarti&rft.au=Coffman%2C+Karen+J&rft.au=Walker%2C+Gregory+S&rft.au=Ryder%2C+Tim+F&rft.date=2013-09-01&rft.eissn=1520-6017&rft.volume=102&rft.issue=9&rft.spage=3277&rft.epage=3293&rft_id=info:doi/10.1002%2Fjps.23542&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon |